Damora Therapeutics (DMRA) EBIT (2019 - 2026)
Damora Therapeutics posted quarterly EBIT of -$30.8 million for Q1 2026, down 1085.49% year-on-year from $3.1 million in Q1 2025, and up 84.72% on a QoQ basis from -$201.7 million in Q4 2025.
Damora Therapeutics (DMRA) has 8 years of EBIT data on file, last reported at -$30.8 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT fell 1085.49% year-over-year to -$30.8 million; the trailing twelve-month figure through Mar 2026 stood at -$239.1 million (down 1150.57% YoY), and the FY2025 full-year result was -$210.9 million, down 847.31% from the prior year.
- EBIT for Q1 2026 stood at -$30.8 million, up from -$201.7 million in the prior quarter.
- Across five years, EBIT topped out at -$2.6 million in Q1 2025 and bottomed at -$201.7 million in Q4 2025.
- The 5-year median for EBIT is -$8.6 million (2023), against an average of -$21.5 million.
- The widest annual swing landed in 2024, when EBIT jumped 57.45%; it then tumbled 2739.99% in 2025.
- A 5-year view of EBIT shows it stood at -$13.5 million in 2022, then surged by 50.68% to -$6.7 million in 2023, then dropped by 6.46% to -$7.1 million in 2024, then sank by 2739.99% to -$201.7 million in 2025, then soared by 84.72% to -$30.8 million in 2026.
- The last three EBIT figures came in at -$30.8 million (Q1 2026), -$201.7 million (Q4 2025), and -$3.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Damora Therapeutics | 853.36 Mn | 650.97 Mn | - | -30.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.81 Mn |
| Dec 31, 2025 | -201.70 Mn |
| Sep 30, 2025 | -3.16 Mn |
| Jun 30, 2025 | -3.42 Mn |
| Mar 31, 2025 | -2.60 Mn |
| Dec 31, 2024 | -7.10 Mn |
| Sep 30, 2024 | -3.84 Mn |
| Jun 30, 2024 | -5.58 Mn |
| Mar 31, 2024 | -5.74 Mn |
| Dec 31, 2023 | -6.67 Mn |
| Sep 30, 2023 | -8.58 Mn |
| Jun 30, 2023 | -11.16 Mn |
| Mar 31, 2023 | -13.49 Mn |
| Dec 31, 2022 | -13.53 Mn |
| Sep 30, 2022 | -13.62 Mn |
| Jun 30, 2022 | -17.12 Mn |
| Mar 31, 2022 | -16.94 Mn |
| Dec 31, 2021 | -13.47 Mn |
| Sep 30, 2021 | -12.94 Mn |
| Jun 30, 2021 | -12.27 Mn |
| Mar 31, 2021 | -13.55 Mn |
| Dec 31, 2020 | -11.30 Mn |
| Sep 30, 2020 | -10.17 Mn |
| Jun 30, 2020 | -6.34 Mn |
| Mar 31, 2020 | -5.83 Mn |
| Dec 31, 2019 | 24.85 Mn |
| Sep 30, 2019 | 4.83 Mn |